Skip to main content
PLOS One logoLink to PLOS One
. 2025 Sep 18;20(9):e0332816. doi: 10.1371/journal.pone.0332816

Reward network mechanism in anhedonia and depression

Xiaoxiao Sun 1,#, Chenxuan Jin 1,2,#, Chun Cui 3, Zhaohua Chen 1, Qin Dai 1,4,*
Editor: Rosemary Bassey,5
PMCID: PMC12445566  PMID: 40966302

Abstract

Background

Depression is one of the most burdensome mental disorders. Anhedonia, a core symptom of major depressive disorder (MDD), is characterized by abnormal resting-state reward network (RN). However, it is unclear whether anhedonia symptom and depressive episode share similar resting-state RN mechanism, as well as whether the RN mechanism is a state or trait-like marker of depression. This study aims to clarify the two points by recruitingboth current and remitted depression.

Methods

Using functional Magnetic Resonance Imaging (fMRI) scans, this study observed the resting-state RN function connectivity (with the seed of ventral striatum) in patients with remitted depression (RMD, n = 27) and current depression (n = 30) and 33 normal controls. The low-frequency fluctuation (ALFF) and T1 image were further analyzed.

Results

Three groups differed in anhedonia scores, with highest anhedonia in the MDD group and lowest anhedonia in the NC group. In total sample, higher anhedonia was correlated with weaker connectivity between the striatum seed and the putamen, inferior frontal cortex, insula, AC, and thalamus, while in the RMD group, anhedonia correlated with higher AC, thalamus, and caudate connectivity. In resting-state function connectivity, the MDD group possessed weaker connectivity between the striatum seed and inferior frontal cortex and insula, while the RMD group showed weaker connectivity with the caudate, and both the MDD and RMD groups possessed lower connectivity with the AC. ALFF data indicated a higher anterior cingulate (AC) activation in the MDD group than the RMD group.T1 image indicated a bigger thalamus volume in the MDD group than the RMD group.

Conclusions

The current study is among the first to confirm that RMD patients possess different RN pattern compared with MDD. Importantly, caudate playsa unique role in depression remission, AC and thalamus mechanisms are trait-like markers of depression. Surprisingly, insula and inferior frontal mechanisms share by depressive episode and anhedonia, while putamen discriminates depressive episode and anhedonia. The results suggest candidate biomarkers for the treatment of clinical depression.

Introduction

Depression is one of the most burdensome mental disorders [1], which has not been well prevented (3% to 22.5% incidence) [2] or cured (one-third non-responder and high recurrence:60% after 5 years, 67% after 10 years, and 85% after 15 years) [3] despite decades of efforts. To better control depression, increasing studies have assessedthe neural alterations of depression in an attempt to reveal potential cerebral mechanisms underlying the occurrence and recurrence of major depressive disorder (MDD) [4]. Neuro-imaging findings have identified that MDD patients showed decreased reward network (RN) connectivity (mainly in the prefrontal-striatal regions) [5,6], which comprised of ventral and dorsal striatum, medial prefrontal-cortex (including orbito-frontal cortex), anterior cingulate, medial temporal lobes, and ventral tegmental area [7]. Blunted left ventral striatum response to reward was associated with a lifetime depression diagnosis [8]. Recent review indicated that compared with healthy controls, patients with MDD exhibited common activity decreases in the right striatum (putamen, caudate) and subgenual ACC [9]. Functional connectivity between the ventral striatum (key region of the RN) and the default mode network was found to be positively and significantly associated with depression scores [10]. Moreover, RN connectivity was found to be correlated with antidepressant therapy in which changes in the sensitivity of the neural reward were positively correlated with the improvement of depressive symptoms [11]. Consistently, MDD patients who do not respond to repetitive transcranial magnetic stimulation therapy were found to show significantly weaker connectivity in the traditional reward network [12]. These results suggest a role of the neural RN in depressive episode.

A core symptom of major depressive disorder is anhedonia, which has beenoften defined as hyposensitivity to reward (this perspective focuses on emotional arousal to reward) [13], and also defined sometimes as diminished anticipation and pursuit of reward (this perspective focuses on motivation and behaviorresponses to reward) [14]. The cerebral foundation of anhedonia has been explored. In which, the hypo-arousalcould be well observed in resting-state neural images [ 12, 15], while the motivation and behavior responses could be observed by money-reward task [16]. Specifically, it was found that anhedonia was correlated with non-response to transcranial magnetic stimulation which had lower resting-state connectivity in the classical reward pathway [12]. Consistently, a disturbance in resting-state reward network has been confirmed to be correlated with depressive anhedoniain rats [15]. Change in anhedonia scores negatively correlated with rsFC after antidepressant treatment [17]. A previous study further reported that anhedonia symptom and depressive mood were associated with similar striatal circuits in MDD patients with money-reward task [16]. Indeed, RN was indicated associated with both anhedonia and depression [18]. The results indicated a role of RN, especially the ventral striatum, in anhedonia. However, anhedonia is a core symptom of depressive episode, anhedonia itself can not represent a depressive episode [19]. Specifically, to be diagnosed with MDD, one must be in depressed mood or anhedonia which causes social/occupational impairment [20], i.e., anhedonia is only one symptom of MDD which might be exempted from experiencing by some patients with MDD [19]. If some patients experience anhedonia while others not, it thus could be deduced that the neural mechanism underling MDD may be differed but alike with anhedonia (Hypothesis 1), since that MDD was formed by broader symptoms such as sadness or insomnia which were very different from anhedonia [21,22]. However, further evidenceis needed to confirm whether anhedoniasymptom and depressive episode share similarbutsubtly-differentresting-state reward network mechanism, clarifying this issue might be important to suggest candidate cortexfor clinical depression therapy, especially for anhedonia-type depression.

Importantly, depression is a highly recurrent mood disorder [23]. Comparison between current and remitted depression may suggest trait- or state- marker of depression, i.e., commonality between them suggests a trait-like marker while difference between them suggests a state-like marker [2426]. However, we do not know whether the RN mechanism is a state marker or a trait-like character closely correlated with the onset or recurrence of depression. Unfortunately, although a few studies observed neural differences between current and remitted depression [27], most studies explored the neural activation of current and remitted depression separately [5,12,2830]. Among these studies, current depression was observed most often [5,12,30], while few studies focused on remitted depression [28]. A limited number of researches reported that remitted depression hasa different RN activation during a reward process (hyperactivation while anticipating a reward in bilateral anterior cingulate gyrus and right midfrontal gyrus and hypoactivation during reward outcomesin orbital frontal cortex, right frontal pole, left insular cortex, and left thalamus) [28]. In contrast, in another study, hypoactivation in the putamen and caudate of a remitted patient was observed [29]. It is well known that the current and remitted depression differin symptoms [31] and neural foundation [25,26], it could be assumed that they differ significantly in resting-state RN mechanism (Hypothesis 2). Therefore, this study included patients with remitted depression (RMD) to confirm the role of RN mechanism during the remission of depression, and further compare with that of MDD to confirm whether RN mechanism is a state marker of depressive episode or a trait-like mechanism related to the occurrence and recurrence of depression.

Thus, the present study had two aims. The first was to explore thedifferencesinthe RN mechanismsbetween anhedonia and depressiveepisode. The second was to explore the differencesinthe RN mechanismbetween current and remitted depression. Our hypotheses wereas follows: (1) Anhedonia and depressive episodemay share similar but subtly-different RN mechanism. (2) Current and remitted depression may share different RN mechanisms.

Methods

Participants

To compare the neural network connectivityin individuals with different depressive statuses, we recruited never depressed normal controls (NCs) and patients with remitted and current depression from April of 2021 to January of 2022. The depressed patients were recruited throughthe psychiatrists inclinic, and the healthy controls were recruited via an advertisement. The depressive symptoms were evaluated using the Beck Depression Inventory-II (BDI-II) [32,33], the Patient Health Questionnaire (PHQ-9) [34,35], the Structured Clinical Interview for Diagnostic and Statistical Manual for Mental Disorders-5th (SCID) [36] and the Hamilton Depression Rating Scale (HDRS, 24 items) [37]. To investigate the anxiety status of the participants, the Beck Anxiety Inventory-II (BAI) was also used. The inclusion criteria for the three groups were as follows: the normal controls should not have a lifetime or current psychosis or depression, the MDD patients should be diagnosed as having major depression by a clinical psychiatrist and have had two or more episodes according to the symptoms of the DSM-5th [38],and the RMD individuals should be antidepressant free for 3 months or longer and recovered from their last episode for 6 months or longer (the mean remission time was 9.24 months). The exclusion criteria were as follows: current or history of any psychopathology and/or drug and alcohol abuseinfection, drug dependence, allergies within the last half month, physical trauma, severe physical disease, learning or cognitive disability. Due to the potential risk from a fMRI scan, subjects with the following situations were also excluded: being pregnant or having a pacemaker, any magnetic or metal materials within the whole body, or having epilepsy or a history of brain surgery. The recruitment details were shown in our previous work and in S1 Fig [39]. Thirty MDD patients, twenty-seven remitted individuals, and thirty-three normal controls were recruited. All MDD patients took medicine (eight were taking fluoxetine hydrochloride, 20–40 mg; ten were taking mirtazapine, 30–40 mg; and twelve were taking paroxetine hydrochloride, 20–30 mg). See S1 Fig for the details.

Questionnaire

The PHQ-9 and BDI-II were utilized to evaluate the levels of depression. The PHQ-9 assessed the symptoms of depressioncorresponding to the frequency of 9 diagnostic items ofmajor depression, and the BDI-IIexamined the severity of depression with 21items [32,40]. The first item (frequency: loss of interest and pleasure) of PHQ and the fourth item (severity: loss of pleasure) of BDI-II were further used to evaluate the anhedonia symptoms of subjects. The BAI also examinedthe level of anxiety with 21items [40].

Procedures

All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki Declaration and its later amendments or comparable ethical standards. The study protocol including participants’capacity to provide consentin accordance with the Declaration of Helsinki was approved by the Ethics Committee of Human Research of the Army Medical University (2020-036-02) and Chinese Clinical Trial registry center (ChiCTR2100044258). The clinical patients with MDD were screened and recruited by the psychiatrists in clinicbased on the SCID and the HDRS. The potential subjects (patients and normal controls) were screened for recruitment andtheircapacity to provide consentby trained personnel withdoctoral degreewho major in psychology via telephone, and qualified participants were scheduled for appointments after the interview via telephone. After the subjects arrived, they were orally informed about the detailed procedure of this study and were further informed about their right to quit any time during the study without any negative outcome. After the subjectssigned on the written informed consent forms, a 10-minute rest period was allowed before the formal study to help subjects to become familiar with the study environment.After the study, participants were available with free psychological consultation and gifted (50 Yuan for each participant).

MRI image acquisition

The brain images were obtained from a whole-body MRI system (Germany, Erlangen,3.0-T Siemens TimTrio) with a 12-channel phased-array head coil, located at Southwest Hospital of Chongqing, China. The image data were scanned via single shot T2-weighted EPI (echo planar imaging, TR/TE = 2000/30 ms, reconstruction matrix = 64 × 64, flip angle = 90◦, FOV = 384 mm, voxel size = 3.0 × 3.0 × 3.0 mm3, 4 mm slice thickness with 1 mm gap, and number of slices foreach volume = 36). The duration of the scan for the resting state was 8 minutes (240 volumes). The anatomical images were obtained viathe 3D-T1MPRAGE protocol (TI/TR/TE = 900/2530/2.34 ms, reconstruction matrix = 256 × 256, flip angle = 7◦, slice thickness = 1 mm, FOV = 256 mm, and number of slices = 192).

MRI image analyses

The cerebral activation images were processedusingSPM8.

Preprocessing The first 10 scan images were removed. Then, the remaining images were preprocessed via SPM8. The brief procedures included the following: (1) slice timing, (2) realignment, (3) coregistration, (4) segmentation, (5) normalization (via DARTEL with a re-sampling rate of 3 × 3 × 3mm3 (1 × 1 × 1mm3 for anatomic images)), and (6) smoothing (size of kernel smoothing = 6 mm (FWHM)). The head motion, cerebrospinal fluid, and white matter were regressed out during the preprocessing with DPARSFA [41].

Resting-state data

REST 1.8 was used to analyze the amplitude of low-frequency fluctuation (ALFF) of resting state [41]. In general, linear regression was conducted on data after preprocessing to remove linear tendency. Hamming band-pass filter was then carried out to remain thesignals between 0.01 and 0.08 Hz (low-frequency). The ALFF value of whole-brain voxel was computed, which was used to divide the average ALFF, and resulted in a standard ALFF value [42].

The functional connectivity between cerebral cortexes was analyzed using REST 1.8 (Resting-State fMRI Data Analysis Toolkit) [43], andautomated anatomical labeling (AAL) was used [44]. The MNI coordinates of the ventral striatum (21, 9, 0) were consistent with the literature [45]. RN connectivity was obtained from the whole-brainfunctional connectivity with this ventral striatum seed. See the supplementary materials (S2 Fig) for details.

T1 image

T1 image was analyzed with SPM8 via DARTEL (voxel-based morphometry, VBM) [44]. The brief procedures included the following: (1) segmentation; (2) normalization; (3) nonlinear registration; (4) coregistration; (5) smoothing. One-way ANOVA was conducted on T1 image data between the three groups.

Statistics

One-way ANOVA was conductedon T1 and ALFF image data andthe functional connectivity between the three groups. A subsequent independent t-test was conducted in each of the two group comparisons (AlphaSim correction, corrected pvalue < .01 (uncorrected p value < .001), in a brain volume of 61 × 73 × 61, estimated spatial smoothness of 6 mm, and a minimum cluster size of 26 voxels or 702 mm3 (AFNI; https://afni.nimh.nih.gov/pub/dist/doc/manual/AlphaSim.pdf), RN mask (S2 Fig)). Moreover, a correlation analysis was also conducted between the value of resting-state RN connectivityand anhedonia scoresusing REST 1.8 [43]. The analyzed images were configured using Rest Viewer (overlaid above a ch2 bet.nii template). Age and gender were controlled as covariables.

The demographic information and scores of scales of the participants were compared via one-way ANOVA, while the ratio of gender and anhedonia were evaluated by χ2 test.

Results

General information (Table 1)

Table 1. General information.

Gender
(M/F)
Age Education (years) Episodes Duration of illness (years) FD value of head motion Score of PHQ Score of BDI Score of HDRS Score of BAI
NC (n = 33) 11/22 48.85 ± 12.38 12.33 ± 2.33 0.13 ± 0.05 1.12 ± 1.24 2.21 ± 1.45 1.92 ± 1.24 1.77 ± 1.36
MDD (n = 30) 7/23 48.77 ± 11.88 12.47 ± 2.69 2.80 ± 1.35 9.20 ± 1.94 0.12 ± 0.06 21.63 ± 5.25 34.23 ± 10.08 23.27 ± 2.95 12.97 ± 6.75
RMD (n = 27) 11/16 49.56 ± 10.77 12.11 ± 3.52 2.63 ± 1.33 8.67 ± 2.66 0.15 ± 0.06 5.41 ± 3.87 6.74 ± 4.59 5.67 ± 3.11 4.63 ± 2.63
P (ANOVA/χ2 test) 0.368 0.962 0.894 0.634 0.387 0.124 <0.001 <0.001 <0.001 <0.001

Note: M = male. F = female. BAI = Beck Anxiety Inventory. BDI-II = Beck Depression Inventory-II. PHQ = patient health questionnaire. HDRS = the Hamilton Depression Rating Scale. NC = Never disordered healthy Controls. MDD = Major Depressive Disorder. RMD = Remitted depression.

Three groups did not significantly differ in age (F (2,87) = 0.038, partial eta2 = 0.001, p = 0.962), education level (F (2,87) = 0.112, partial eta2 = 0.003, p = 0.894), or male/femaleratio (χ2 = 2.001, p = 0.368, df = 2, N = 90). As hypothesized, they significantly differed on theBDI-II (F (2,87) = 223.166, partial eta2 = 0.84, p < 0.001), PHQ (F (2,87) = 252.477, partial eta2 = 0.853, p < 0.001), HDRS (F (2,87) = 624.037, partial eta2 = 0.94, p < 0.001), and BAI scores (F (2,87) = 58.101, partial eta2 = 0.572, p < 0.001), with the lowest scores in the NC group and the highest scores in the MDD group. The remitted and current depression groups did not significantly differ in the duration of depression or the number of episodes (p > 0.05).The three groups did not significantly differ in headmotion (F (2,87) = 2.137, partial eta2 = 0.047, p = 0.124).

Anhedoniasymptoms of the participants (Table 2)

Table 2. Anhedonia symptom of participants.

Scores of anhedonia item Ratio of anhedonia (present/absent)
PHQ-1st BDI-4th PHQ-1st BDI-4th
NC (n = 33) 0.15 ± 0.57 0.03 ± 0.17 5/28 1/32
MDD (n = 30) 2.57 ± 0.77 2.07 ± 0.83 29/1 30/0
RMD (n = 27) 0.67 ± 0.78 0.41 ± 0.57 13/14 10/17
F/χ2 99.031** 106.399** 42.106** 60.705**

Note: ** p < 0.01.

Due to the close relationship between anhedonia and depressive episode, ANOVA was conducted on the anhedonia items of the questionnaires to compare the anhedonia symptom between groups. The results confirmed the expected differences between three groups on the scores of anhedonia item (first item) of the PHQ (F (2,87) = 99.031, p < 0.001, partial eta2 = 0.70) and the fourth item of the BDI-II (F (2,87) = 106.399, p < 0.001, partial eta2 = 0.71), with the lowest scores in the normal controls and highest scores in the MDD group. Consistently, more individuals in the MDD group (all except one) reported suffering from anhedonia compared with the other two groups, based on the scores of first item of PHQ (χ2 = 42.106, df = 2, N = 90, p < 0.001) and fourth item of BDI-II (χ2 = 60.705, df = 2, N = 90, p < 0.001).

Correlation between functional connectivity and anhedonia (Table 3)

Table 3. Correlation between RN function connectivity and anhedonia.

Cortex L/R Cluster (k) r MNI
x y z
BDI4-all subjects
 Putamen R 14 −0.37** 15 6 −6
 Inferior frontal cortex L 21 −0.30** −39 24 6
 Inferior frontal cortex R 47 −0.29** 54 24 3
 AC L 57 −0.36** −12 36 0
 Insula R 43 −0.39** 36 9 9
PHQ1-all subjects
 Thalamus R 27 −0.26* 9 −9 3
 Putamen L 24 −0.22* −30 6 −3
 Insula R 24 −0.35** 36 9 12
 Inferior frontal cortex L 21 −0.30** −39 18 9
RMD- BDI4
 Caudate R 12 −0.57** 6 9 −3
 Thalamus R 50 0.52** 6 −12 3
 Suprior Frontal Gyrus R 46 −0.70** 9 12 66
RMD- PHQ1
 Caudate R 38 0.53** 12 12 6
 AC R 50 0.47* 3 33 21
 Thalamus R 23 0.55** 18 −12 9

Note: L: left, R: right, * p < 0.05, ** p < 0.01. MDD = Major Depressive Disorder. RMD = Remitted depression. BDI4 = Anhedonia item of Beck depression inventory. PHQ1 = Anhedonia item of patient health questionnaire.

To observe the relationship between neural function connectivity and depressive anhedonia, correlations between the value of resting-state RN connectivity and the anhedonia scores in all participants and sub-groups were conducted using REST 1.8. In total sample, a negative correlation was found between the severity of anhedonia (4th item of BDI-II, Fig 1) and striatum functional connectivity in the right putamen (r = −0.39, k = 14, p < 0.05), left inferior frontal cortex (r = −0.31, k = 21, p < 0.05), right inferior frontal cortex (r = −0.38, k = 47, p < 0.05), left AC (r = −0.41, k = 57, p < 0.05), and right insula (r = −0.43, k = 43, p < 0.01); in addition, a negative correlation was found between the frequency of anhedonia (1st item of PHQ, Fig 2) and striatum functional connectivity in the right insula (r = −0.42, k = 24, p < 0.05), left inferior frontal cortex (r = −0.33, k = 21, p < 0.05), left putamen (r = −0.29, k = 24, p < 0.05), and right thalamus (r = −0.34, k = 27, p < 0.05). In the RMD group, a positive correlation was found between the severity of anhedonia (Fig 3) and striatum functional connectivity in the right thalamus (r = 0.78, k = 50, p < 0.05); a negative correlation was found between the severity of anhedonia and striatum functional connectivity in the right caudate (r = −0.65, k = 12, p < 0.05) and right superior frontal gyrus(r = −0.81, k = 46, p < 0.01); and a positive correlation was found between the frequency of anhedonia (Fig 4) and striatum functional connectivity in the right caudate (r = 0.77, k = 38, p < 0.01), right AC (r = 0.79, k = 50, p < 0.01), and right thalamus (r = 0.77, k = 23, p < 0.01). No significant correlation between anhedonia and striatum connectivity was foundin the NC and MDD groups. See Figs 12,Table 3, and S3 Fig (scatterplots) for details.

Fig 1. Negative correlation between insula, inferior frontal, and putamen connectivity and depressive anhedonia (BDI4).

Fig 1

Fig 2. Negative correlation between insula, inferior frontal, and putamen connectivity and depressive anhedonia (PHQ1).

Fig 2

Fig 3. Negative correlation between caudate connectivity and positive correlation between thalamus and ACconnectivityand depressive anhedonia in RMD group (BDI4).

Fig 3

Fig 4. Negative correlation between caudate connectivity and positive correlation between thalamus and ACconnectivityand depressive anhedonia in RMD group (PHQ1).

Fig 4

Resting-state activity and function connectivity in current and remitted depression

Functional connectivity (Table 4).

Table 4. RN function connectivity in current and remitted depression (striatum seed).
Cortex L/R Cluster (k) MNI
Three groups F x y z
 Caudate L 11 14.89** −18 −3 −21
 Anterior Cingulate L 43 6.45* −12 33 6
 Middle Cingulate L 14 15.39* −3 −3 33
MDD-NC t x y z
 Insular R 27 −4.40** 36 9 9
 Inferior frontal cortex R 130 −3.49* 54 21 24
 Anterior Cingulate L 119 −4.61* −12 39 0
RMD-MDD t x y z
 Inferior frontal cortex R 55 3.83* 57 21 15
 Caudate R 26 −3.78* 6 −9 15
 Caudate L 27 −3.54* −18 −3 21
 Insula R 10 3.41* 21 12 −9
 Middle Frontal Gyrus R 43 3.96* 36 33 30
RMD-NC t x y z
 Caudate L 117 −6.03** −18 −3 21
 Cingulate gyrus R/L 76 −5.17** −3 −3 33

Note: L: left, R: right, * p < 0.05, * p < 0.05, ** p < 0.01.

One-way ANOVA (analyzed using REST 1.8) on the functional connectivity between the striatum seed and RN indicated that the three groups differed in their connectivity between the striatum seed and the left caudate (k = 21, p < 0.01), the left anterior (k = 43, p < 0.05), and the middle cingulate gyrus (k = 24, p < 0.05), S4 Fig. Further two-sample t-tests (AlphaSim correction, corrected p-value < 0.01) indicated that compared with the normal controls, the patients with current depression exhibited weaker connectivity between the striatum seed and the right insula (k = 27, p < 0.01), the right inferior frontal cortex (k = 130, p < 0.05), and the left anterior cingulated gyrus (AC) (k = 119, p < 0.05) (Fig 5). In contrast, compared with the MDD group, individuals with remitted depression showed stronger connectivity between the striatum seed and the right inferior frontal cortex (k = 55, p < 0.05), the right insula (k = 20, p < 0.05), and the right middle frontal gyrus (k = 43, p < 0.05) and weaker connectivity between the striatum seed and the left and right caudate (k = 27, k = 26, p < 0.05) (Fig 6). They also showed weaker connectivity between the striatum seed and the left caudate (k = 117, p < 0.01) and the cingulated gyrus (k = 76, p < 0.01) compared with the normal controls (Fig 7).

Fig 5. Lower inferior frontal, anterior cingulated and insula connectivity in the MDD group compared with the NC group.

Fig 5

Fig 6. Higher inferior frontal and insula connectivity and lower caudate connectivity in the RMD group compared with the MDD group.

Fig 6

Fig 7. Lower caudate and cingulate connectivity in the RMD group compared with theNC group.

Fig 7

Amplitude of low-frequency fluctuation (ALFF).

An ANOVA was conducted on the ALFF data, which indicated a difference between three groups in the right ACC (k = 13, F (2,87) = 7.04, x = 9 y = 21 z = −9, p < .01). A further two-sample t test (AlphaSim correction, corrected p value < .01) showed that the RMD group had a lower activity inthe right ACC (k = 17, t = 3.09, x = 9 y = 21 z = −6, p < .01) compared with the MDD group.

T1 image.

An ANOVA was conducted on the T1image, which indicated a difference between the three groups in the right thalamus (k = 40, x = 9 y = −24 z = 15, F (2,87) = 7.19, p < .01). A further two-sample t test (AlphaSim correction, corrected p value < .01) showed that the RMD group had a smaller volume inthe right thalamus (k = 79, x = 12 y = −24 z = 18,t = 3.64, p < .01) compared with MDD group. See S5 Fig for details.

Discussions

The current study found that RMD patients possess different RN pattern of anhedonia. Potentially and importantly, caudate played a unique role in depression remission, AC and thalamus mechanisms were trait-like markers of depression. Surprisingly, insula and inferior frontal mechanisms shared by depressive episode and anhedonia, while putamen discriminated depressive episode and anhedonia.

Our result found that three groups differed in anhedonia scores, with highest anhedonia in the MDD group andlowest anhedoniain the NC group. This finding support that anhedonia is a core symptom of clinical depression [13], which is significantly differed in different depressive status.This study reports and compares anhedonia symptoms of current and remitted depression in one single study, which enriches the understanding about the anhedonia during the process of depression. Potentially, the differences in resting-state RN mechanism between groups may indicate the neural mechanisms for anhedonia with different levels.

The current study confirmed a correlation between RN connectivity and depressive anhedonia. The findings suggested that in the total sample, there was a consistent and negative correlation between anhedonia and striatum connectivity with the insula, inferior frontal cortex, AC, thalamus, and putamen. In the RMD group, there was a different correlation model, i.e., a consistent positive correlation between the severity and frequency of anhedonia and the AC, thalamus, a different negative correlation between the severity of anhedonia and striatum connectivity with the caudate. No significant correlation between anhedonia and striatum connectivity was indicated in the NC and MDD groups, which suggested that too low or too high onprevalence of anhedonia in the subgroup muted the correlation between symptoms of anhedonia and striatum connectivity, while a proportionate occurrence of anhedonia in the RMD group could reflect acorrelation trend. Although anhedonia score goes MDD > RMD > NC, however, as discussed previously, anhedonia is a core symptom of depressive episode, anhedonia itself can not represent a depressive episode [20]. Thus, the correlation between anhedonia score and RN activation can not be equal to the correlation between depressive scores and RN activation: anhedonia and depressive episode share similar but subtly-different RN mechanism (Hypothesis 1). Interestingly,in all group analysis, right putamen was negatively correlated with severity of anhedonia, while left putamen was negatively correlated with frequency of anhedonia, which was consistent with previous reporting [46]. Moreover, in RMD group analysis, right caudate negatively correlated with severity of anhedonia and positively correlated with frequency of anhedonia, while this cortex did not report a correlation in all group analysis, which verified recent animal experiment in a sense [47]. The reason might be that the reward network mechanisms underling the severity and frequency of anhedonia are different (hemisphere preference in putamen activation, and direction preference in caudate activation in RMD), since that high frequency (almost every day) may be mild in severity (I don’t like things as usual), which needs further evidence. The current study confirmed that RMD patients possess a different RN pattern of anhedonia compared with MDD(Hypothesis 2), first report in its kind, as far as we know, which enriches the understanding about the neural mechanism underling anhedonia during the process of depression. Together, the correlation results suggested unique roles ofputamen, insula and inferior frontal cortex in anhedonia, a role of caudate in the remission of depression, and a role of AC and thalamus as trait-like characteristic of anhedonia and depression remission, which were shared by the whole sample and RMD group.

Analysis of the functional connectivity indicated that the MDD group showed weaker connectivity between the striatum seed and the inferior frontal cortex and insula. In contrast, the RMD group possessed stronger connectivity between the inferior frontal cortex and insula and the striatum seed. The findings suggested that weaker connectivity between the striatum seed and the inferior frontal cortex and insula contributes to episodes of depression, while the remission of depression compensates for the decreased functional connectivity. The results indicate a potential insula and inferior frontal mechanism in depressiveepisode, i.e., decreased connectivity between the striatum and insula and inferior frontal cortex might result in an episode of depression [4850], which broadens our understanding of the RN mechanism in depressive episode.

One improvement of the current study over the previous literature was that this study observed the RN mechanism in remitted depression. The functional connectivity results confirmed that the RMD group exhibited weaker connectivity between the striatum seed and caudate compared with patients with current depression and the normal controls (Hypothesis 2).The results suggest that the remitted patients might maintain an emotional balance through decreased connectivity between the striatum seed and caudate, which reveals a potential caudate mechanism in the recovery of depression, i.e., individuals with remitted depression might reach an emotional balance via decreased connectivity between the ventral striatum and caudate [51].

Importantly, both patients with current and remitted depression possessed weaker connectivity between the striatum seed and AC, while MDD group indicated higher ALFF amplitude in AC compared with RMD group. The results indicated that the weaker connectivity between the striatum seed and the AC remained unchanging before and after the remission of depression, which might be a trait-like biomarker of depression constantly correlated with the occurrence or recurrence of depression. Combined with task-state fMRI in our previous reporting [52], i.e., MDD group showed higher activation in AC during a cue-target task compared with RMD group, the results suggest a potential antidepressant target in clinic, i.e., the AC might be a candidate cortex in the prevention and treatment of depression.

T1 scan data was further analyzed and indicated that MDD patients had bigger volume in thalamus compared with the RMD group. Combining the T1 result with correlation findings and the functional connectivity results, our data suggested that the insula and inferior frontal cortex characterized by anhedonia and depressive episode, the caudate was more involved in the remission of depression, the putamen was involved only in the depressive anhedonia, and the AC and thalamus represented a trait-like mechanism in anhedonia, depressive episode and remission. The results confirm that anhedonia is a core symptom of depressive episode, which might be a core pathological mechanism underlying episode of depression [16,53], i.e., there areshared AC, thalamus, insula, and inferior frontal mechanisms between depressive episode and anhedonia, however, anhedonia has unique putamen mechanism (Hypothesis 1).

Limitations: First, the sample size was small in this study, which affectedthe explanatory power of ourfindings. Second, the brain volume or intelligence level of subjects were not evaluated,which is common in the research using fMRI [54]. Third, the anhedonia score was evaluated by two items of scales (The first item of PHQ and the fourth item of BDI-II) instead of more detailed instrument, and the neural activation of anhedonia was observed only by resting-state data which could be well observed in resting-state neural image [ 12, 15]. Finally, patients with current episode were all medicated, which has been confirmed thatthere was no obvious effect of medicine on cerebral connectivity [55,56].

Notably, this study included patients with current and remitted depression and confirmed that MDD and RMD patients possess different RN pattern, as well as depressive episode and anhedonia.The findings help to suggest candidate cortex in the treatment of depression. Specifically, caudate involves more in remitted depression, which might be an indicator of remitted stage, and be a potential target in future antidepressant treatment such as deep brain stimulation or medication. Putamen indicatesonly anhedonia but not depressive episode, which might be used to discriminate anhedonia and depressive episode. Insula and inferior frontal involve in both depressive episode and anhedonia, which might be cortex markers of both situations. Notably, AC and thalamusare trait-like markers of bothcurrent and remitted depression, which might involve in different stages of depressive progress, and reflected trait-like neural changes in depression. Future neural experiments including both MDD and RMD are warranted to confirm these findings.

Conclusions

The current study is among the first to confirm that RMD patients possess different RN pattern of anhedonia compared with MDD. The findings that the AC, caudate, insula, and inferior frontal cortexes function differently in anhedonia, depressive episodes, and depression remission, provide important suggestions for the therapy of clinical depression, i.e., the caudate is more involved in the recoveryfrom depression, the putamen is involved more in anhedonia, the insula and inferior frontal cortex represent depressive episodes and anhedonia, and the AC and thalamus represent anhedonia, depressive episodes, and depression remission. Hence, the findings offerreliable evidence for the caudate mechanism in remitted depression, the insula and inferior frontal mechanisms in depressive episodes/anhedonia, and the trait-like AC and thalamus mechanisms in both anhedonia/depressive episodes and remission, which suggest candidate biomarkers for the treatment of clinical depression.

Supporting information

S1 Fig. Flow chart of participant recruitment.

(TIF)

pone.0332816.s001.tif (189.4KB, tif)
S2 Fig. The reward network (RN, ventral striatum seed, 21, 9, 0).

(TIF)

pone.0332816.s002.tif (1.2MB, tif)
S3 Fig. Scatterplots of correlation between functional connectivity and depressive anhedonia.

(TIF)

pone.0332816.s003.tif (290.6KB, tif)
S4 Fig. Group difference on function connectivity with the whole brain (striatum seed).

(TIF)

pone.0332816.s004.tif (1.8MB, tif)
S5 Fig. Bigger thalamus volume in MDD compared with the RMD group.

(TIFF)

S1 Data. RN group data.

(XLSX)

pone.0332816.s006.xlsx (13.8KB, xlsx)

Data Availability

The behavioral data that support the findings of this study were included in Supplementary materials. Due to reframing from military funding (2021HL003 and 2023yjsB02), the neural data could not be placed publicly and was available from the corresponding author upon reasonable request. To ensure the long term stability and availability of data, the neural data was packed and stored in three copies by a non-author institution (Military Psychology Committee institute, Chinese Society of Social Psychology) to ensure persistent or long-term data storage and availability, which was available from the official email address of this committee (jsxlxzwh@163.com).

Funding Statement

Doctor Dai claimed that this work was supported by Social Science Foundation of Chongqing (2023NDYB94), the Key project and innovation project of People's Liberation Army of China (2021HL003), and the education project of Army medical university (2023yjsB02). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript, only reframed the sharing of original neural data.

References

  • 1.Smith K. Mental health: A world of depression. Nature. 2014;515(7526):180–1. [DOI] [PubMed] [Google Scholar]
  • 2.Rizo C, Deshpande A, Ing A, Seeman N. A rapid, Web-based method for obtaining patient views on effects and side-effects of antidepressants. J Affect Disord. 2011;130(1–2):290–3. doi: 10.1016/j.jad.2010.07.027 [DOI] [PubMed] [Google Scholar]
  • 3.Hardevald F, Spijker J, De Graaf R, Nolen WA, Beekman ATF. Prevalence and predictors of recurrence of major depressive disorder in the adult population. Acta Psychiatrica Scandinavica. 2010;122(3):184–91. [DOI] [PubMed] [Google Scholar]
  • 4.Stickel S, Wagels L, Wudarczyk O, Jaffee S, Habel U, Schneider F, et al. Neural correlates of depression in women across the reproductive lifespan - An fMRI review. J Affect Disord. 2019;246:556–70. doi: 10.1016/j.jad.2018.12.133 [DOI] [PubMed] [Google Scholar]
  • 5.Gong L, He C, Zhang H, Zhang H, Zhang Z, Xie C. Disrupted reward and cognitive control networks contribute to anhedonia in depression. J Psychiatr Res. 2018;103:61–8. doi: 10.1016/j.jpsychires.2018.05.010 [DOI] [PubMed] [Google Scholar]
  • 6.Hassamal S. Chronic stress, neuroinflammation, and depression: an overview of pathophysiological mechanisms and emerging anti-inflammatories. Front Psychiatry. 2023;14:1130989. doi: 10.3389/fpsyt.2023.1130989 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 7.Haber SN, Knutson B. The reward circuit: linking primate anatomy and human imaging. Neuropsychopharmacology. 2010;35(1):4–26. doi: 10.1038/npp.2009.129 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 8.Bondy E, Baranger DAA, Balbona J, Sputo K, Paul SE, Oltmanns TF, et al. Neuroticism and reward-related ventral striatum activity: Probing vulnerability to stress-related depression. J Abnorm Psychol. 2021;130(3):223–35. doi: 10.1037/abn0000618 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 9.Bore MC, Liu X, Huang X, Kendrick KM, Zhou B, Zhang J, et al. Common and separable neural alterations in adult and adolescent depression - Evidence from neuroimaging meta-analyses. Neurosci Biobehav Rev. 2024;164:105835. doi: 10.1016/j.neubiorev.2024.105835 [DOI] [PubMed] [Google Scholar]
  • 10.Hwang JW, Xin SC, Ou YM, Zhang WY, Liang YL, Chen J, et al. Enhanced default mode network connectivity with ventral striatum in subthreshold depression individuals. J Psychiatr Res. 2016;76:111–20. doi: 10.1016/j.jpsychires.2016.02.005 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 11.Takamura M, Okamoto Y, Okada G, Toki S, Yamamoto T, Ichikawa N, et al. Patients with major depressive disorder exhibit reduced reward size coding in the striatum. Prog Neuropsychopharmacol Biol Psychiatry. 2017;79(Pt B):317–23. doi: 10.1016/j.pnpbp.2017.07.006 [DOI] [PubMed] [Google Scholar]
  • 12.Downar J, Geraci J, Salomons TV, Dunlop K, Wheeler S, McAndrews MP, et al. Anhedonia and reward-circuit connectivity distinguish nonresponders from responders to dorsomedial prefrontal repetitive transcranial magnetic stimulation in major depression. Biol Psychiatry. 2014;76(3):176–85. doi: 10.1016/j.biopsych.2013.10.026 [DOI] [PubMed] [Google Scholar]
  • 13.Hamilton JB, Worthy VC, Moore AD, Best NC, Stewart JM, Song M-K. Messages of Hope: Helping Family Members to Overcome Fears and Fatalistic Attitudes Toward Cancer. J Cancer Educ. 2017;32(1):190–7. doi: 10.1007/s13187-015-0895-z [DOI] [PubMed] [Google Scholar]
  • 14.Cipriano-Crespo C, Conde-Caballero D, Rivero Jiménez B, Mariano-Juárez L. Eating experiences and quality of life in patients with larynx cancer in Spain. A qualitative study. Int J Qual Stud Health Well-being. 2021;16(1):1967262. doi: 10.1080/17482631.2021.1967262 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 15.Bolton JL, Molet J, Regev L, Chen Y, Rismanchi N, Haddad E, et al. Anhedonia Following Early-Life Adversity Involves Aberrant Interaction of Reward and Anxiety Circuits and Is Reversed by Partial Silencing of Amygdala Corticotropin-Releasing Hormone Gene. Biol Psychiatry. 2018;83(2):137–47. doi: 10.1016/j.biopsych.2017.08.023 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 16.Quevedo K, Ng R, Scott H, Kodavaganti S, Smyda G, Diwadkar V, et al. Ventral Striatum Functional Connectivity during Rewards and Losses and Symptomatology in Depressed Patients. Biol Psychol. 2017;123:62–73. doi: 10.1016/j.biopsycho.2016.11.004 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 17.Bekhbat M, Li Z, Mehta ND, Treadway MT, Lucido MJ, Woolwine BJ, et al. Functional connectivity in reward circuitry and symptoms of anhedonia as therapeutic targets in depression with high inflammation: evidence from a dopamine challenge study. Mol Psychiatry. 2022;27(10):4113–21. doi: 10.1038/s41380-022-01715-3 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 18.Höflich A, Michenthaler P, Kasper S, Lanzenberger R. Circuit mechanisms of reward, anhedonia, and depression. Int J Neuropsychopharmacol. 2019;22(2):105–18. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 19.Bains N, Abdijadid S. Major depressive disorder. StatPearls. Treasure Island (FL): StatPearls Publishing. 2023. [PubMed] [Google Scholar]
  • 20.Chen X, Liu S, Goraya MU, Maarouf M, Huang S, Chen J-L. Host Immune Response to Influenza A Virus Infection. Front Immunol. 2018;9:320. doi: 10.3389/fimmu.2018.00320 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 21.Ashaie SA, Funkhouser CJ, Jabbarinejad R, Cherney LR, Shankman SA. Longitudinal Trajectories of Post-Stroke Depression Symptom Subgroups. Neurorehabil Neural Repair. 2023;37(1):46–52. doi: 10.1177/15459683221143464 [DOI] [PubMed] [Google Scholar]
  • 22.Sudol K, Conway C, Szymkowicz SM, Elson D, Kang H, Taylor WD. Cognitive, Disability, and Treatment Outcome Implications of Symptom-Based Phenotyping in Late-Life Depression. Am J Geriatr Psychiatry. 2023;31(11):919–31. doi: 10.1016/j.jagp.2023.06.003 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 23.Kessler RC. Epidemiology of depression. In: Hammen IG, Hammen C. Handbook of depression. New York: Guilford Press. 2002. [Google Scholar]
  • 24.Hollon SD. What we got wrong about depression and its treatment. Behav Res Ther. 2024;180:104599. doi: 10.1016/j.brat.2024.104599 [DOI] [PubMed] [Google Scholar]
  • 25.Ironside M, Duda JM, Moser AD, Holsen LM, Zuo CS, Du F, et al. Association of Lower Rostral Anterior Cingulate GABA+ and Dysregulated Cortisol Stress Response With Altered Functional Connectivity in Young Adults With Lifetime Depression: A Multimodal Imaging Investigation of Trait and State Effects. Am J Psychiatry. 2024;181(7):639–50. doi: 10.1176/appi.ajp.20230382 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 26.Shukla R, Newton DF, Sumitomo A, Zare H, Mccullumsmith R, Lewis DA, et al. Molecular characterization of depression trait and state. Mol Psychiatry. 2022;27(2):1083–94. doi: 10.1038/s41380-021-01347-z [DOI] [PubMed] [Google Scholar]
  • 27.Ming Q, Zhong X, Zhang X, Pu W, Dong D, Jiang Y. State-Independent and Dependent Neural Responses to Psychosocial Stress in Current and Remitted Depression. The American Journal of Psychiatry. 2017;174(10):971–9. [DOI] [PubMed] [Google Scholar]
  • 28.Dichter GS, Kozink RV, McClernon FJ, Smoski MJ. Remitted major depression is characterized by reward network hyperactivation during reward anticipation and hypoactivation during reward outcomes. J Affect Disord. 2012;136(3):1126–34. doi: 10.1016/j.jad.2011.09.048 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 29.Hammar Å, Neto E, Clemo L, Hjetland GJ, Hugdahl K, Elliott R. Striatal hypoactivation and cognitive slowing in patients with partially remitted and remitted major depression. Psych J. 2016;5(3):191–205. doi: 10.1002/pchj.134 [DOI] [PubMed] [Google Scholar]
  • 30.Szczypiński JJ, Gola M. Dopamine dysregulation hypothesis: the common basis for motivational anhedonia in major depressive disorder and schizophrenia?. Rev Neurosci. 2018;29(7):727–44. doi: 10.1515/revneuro-2017-0091 [DOI] [PubMed] [Google Scholar]
  • 31.Lozano-Goupil J, Shankman SA, Walther S, Wuethrich F, Maher RE, Grzelak LN, et al. Automatic quantification of hand gestures in current and remitted Major Depressive Disorder during oral expression. J Affect Disord. 2025;389:119684. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 32.Beck AT, Steer RA, Brown GK. Manual for the Beck Depression Inventory. San Antonio, TX: The Psychological Association. 1996. [Google Scholar]
  • 33.Button KS, Kounali D, Thomas L, Wiles NJ, Peters TJ, Welton NJ, et al. Minimal clinically important difference on the Beck Depression Inventory--II according to the patient’s perspective. Psychol Med. 2015;45(15):3269–79. doi: 10.1017/S0033291715001270 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 34.Kroenke K, Spitzer RL, Williams JB. The PHQ-9: validity of a brief depression severity measure. J Gen Intern Med. 2001;16(9):606–13. doi: 10.1046/j.1525-1497.2001.016009606.x [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 35.Liu M, Chang Y, Wang D, Fang J, Carson S, Li B, et al. Validation of the patient health questionnaire (PHQ)-9 and PHQ-2 in patients with COPD in China. BMC Psychiatry. 2025;25(1):637. doi: 10.1186/s12888-025-07052-3 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 36.A P A. Diagnostic and Statistical Manual of Mental Disorders (Fifth ed.). Arlington, VA: American Psychiatric Publishing. 2013. [Google Scholar]
  • 37.Hamilton M. A rating scale for depression. J Neurol Neurosurg Psychiatry. 1960;23(1):56–62. doi: 10.1136/jnnp.23.1.56 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 38.de Graaf LE, Gerhards SAH, Arntz A, Riper H, Metsemakers JFM, Evers SMAA, et al. One-year follow-up results of unsupported online computerized cognitive behavioural therapy for depression in primary care: A randomized trial. J Behav Ther Exp Psychiatry. 2011;42(1):89–95. doi: 10.1016/j.jbtep.2010.07.003 [DOI] [PubMed] [Google Scholar]
  • 39.Dai Q, Feng Z. Deficient interference inhibition for negative stimuli in depression: an event-related potential study. Clin Neurophysiol. 2011;122(1):52–61. doi: 10.1016/j.clinph.2010.05.025 [DOI] [PubMed] [Google Scholar]
  • 40.Liu P, Shu L. Beck Depression Inventory, BDI; Beck Anxiety Inventory, BAI; Hamilton Depression Rating Scale, HDRS (Chinese). In: Wang XW, Ma H. Assessment inventory handbook of mental health. Bei Jing: Chinese journal of mental health. 1999. [Google Scholar]
  • 41.Yan C, Zang Y. DPARSF: A MATLAB toolbox for “pipeline” data analysis of resting-state fMRI. Front Syst Neurosci. 2010;4:13. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 42.Jiang H, Wang A-P, Xu H, Liu Y, Dong Y, Sun Y, et al. Relationship between family support, serum lipid knowledge and quality of life in Chinese breast cancer women with adjuvant endocrine therapy. Support Care Cancer. 2022;30(12):10043–50. doi: 10.1007/s00520-022-07444-1 [DOI] [PubMed] [Google Scholar]
  • 43.Song X-W, Dong Z-Y, Long X-Y, Li S-F, Zuo X-N, Zhu C-Z, et al. REST: a toolkit for resting-state functional magnetic resonance imaging data processing. PLoS One. 2011;6(9):e25031. doi: 10.1371/journal.pone.0025031 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 44.Tzourio-Mazoyer N, Landeau B, Papathanassiou D, Crivello F, Etard O, Delcroix N, et al. Automated anatomical labeling of activations in SPM using a macroscopic anatomical parcellation of the MNI MRI single-subject brain. Neuroimage. 2002;15(1):273–89. doi: 10.1006/nimg.2001.0978 [DOI] [PubMed] [Google Scholar]
  • 45.Walker FR, Pfingst K, Carnevali L, Sgoifo A, Nalivaiko E. In the search for integrative biomarker of resilience to psychological stress. Neurosci Biobehav Rev. 2017;74(Pt B):310–20. doi: 10.1016/j.neubiorev.2016.05.003 [DOI] [PubMed] [Google Scholar]
  • 46.Du H, Xia J, Fan J, Gao F, Wang X, Han Y, et al. Spontaneous neural activity in the right fusiform gyrus and putamen is associated with consummatory anhedonia in obsessive compulsive disorder. Brain Imaging Behav. 2022;16(4):1708–20. [DOI] [PubMed] [Google Scholar]
  • 47.Moraga-Amaro R, Vazquez-Matias DA, Nazario LR, Dierckx RAJO, Stehberg J, Doorduin J, et al. Increased dopamine D2/D3 receptor and serotonin transporter availability in male rats after spontaneous remission from repeated social defeat-induced depression; a PET study in rats. Neurobiol Dis. 2024;202:106727. doi: 10.1016/j.nbd.2024.106727 [DOI] [PubMed] [Google Scholar]
  • 48.Yang Y, Liu S, Jiang X, Yu H, Ding S, Lu Y, et al. Common and Specific Functional Activity Features in Schizophrenia, Major Depressive Disorder, and Bipolar Disorder. Front Psychiatry. 2019;10:52. doi: 10.3389/fpsyt.2019.00052 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 49.Yu H-L, Liu W-B, Wang T, Huang P-Y, Jie L-Y, Sun J-Z, et al. Difference in resting-state fractional amplitude of low-frequency fluctuation between bipolar depression and unipolar depression patients. Eur Rev Med Pharmacol Sci. 2017;21(7):1541–50. [PubMed] [Google Scholar]
  • 50.Wang L, Li F, Mitchell PB, Wang C-Y, Si T-M. Striatal Resting-State Connectivity Abnormalities Associated With Different Clinical Stages of Major Depressive Disorder. J Clin Psychiatry. 2020;81(2):19m12790. doi: 10.4088/JCP.19m12790 [DOI] [PubMed] [Google Scholar]
  • 51.Cheng Y, Xu J, Arnone D, Nie B, Yu H, Jiang H, et al. Resting-state brain alteration after a single dose of SSRI administration predicts 8-week remission of patients with major depressive disorder. Psychol Med. 2017;47(3):438–50. doi: 10.1017/S0033291716002440 [DOI] [PubMed] [Google Scholar]
  • 52.Burns DS, Perkins SM, Tong Y, Hilliard RE, Cripe LD. Music therapy is associated with family perception of more spiritual support and decreased breathing problems in cancer patients receiving hospice care. J Pain Symptom Manage. 2015;50(2):225–31. [DOI] [PubMed] [Google Scholar]
  • 53.Gao K, Sweet J, Su M, Calabrese JR. Depression severity and quality of life of qualified and unqualified patients with a mood disorder for a research study targeting anhedonia in a clinical sample. Asian Journal of Psychiatry. 2017;27:40–7. [DOI] [PubMed] [Google Scholar]
  • 54.Liston C, Chen AC, Zebley BD, Drysdale AT, Gordon R, Leuchter B, et al. Default mode network mechanisms of transcranial magnetic stimulation in depression. Biological Psychiatry. 2014;76(7):517–26. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 55.Baert S, De Raedt R, Schacht R, Koster EHW. Attentional bias training in depression: therapeutic effects depend on depression severity. J Behav Ther Exp Psychiatry. 2010;41(3):265–74. doi: 10.1016/j.jbtep.2010.02.004 [DOI] [PubMed] [Google Scholar]
  • 56.Hernández-Ribas R, Deus J, Pujol J, Segalàs C, Vallejo J, Menchón JM. Identifying brain imaging correlates of clinical response to repetitive transcranial magnetic stimulation (rTMS) in major depression. Brain Stimulation. 2013;6(1):54–61. [DOI] [PubMed] [Google Scholar]

Decision Letter 0

Rosemary Bassey

9 Jul 2025

PONE-D-25-24743 Reward network mechanism in anhedonia and depression PLOS ONE

Dear Dr. Dai,

Thank you for submitting your manuscript to PLOS ONE. After careful consideration, we feel that it has merit but does not fully meet PLOS ONE’s publication criteria as it currently stands. Therefore, we invite you to submit a revised version of the manuscript that addresses the points raised during the review process.

Please submit your revised manuscript by Aug 23 2025 11:59PM. If you will need more time than this to complete your revisions, please reply to this message or contact the journal office at plosone@plos.org. When you're ready to submit your revision, log on to https://www.editorialmanager.com/pone/ and select the 'Submissions Needing Revision' folder to locate your manuscript file.

Please include the following items when submitting your revised manuscript:

  • A rebuttal letter that responds to each point raised by the academic editor and reviewer(s). You should upload this letter as a separate file labeled 'Response to Reviewers'.

  • A marked-up copy of your manuscript that highlights changes made to the original version. You should upload this as a separate file labeled 'Revised Manuscript with Track Changes'.

  • An unmarked version of your revised paper without tracked changes. You should upload this as a separate file labeled 'Manuscript'.

If you would like to make changes to your financial disclosure, please include your updated statement in your cover letter. Guidelines for resubmitting your figure files are available below the reviewer comments at the end of this letter.

If applicable, we recommend that you deposit your laboratory protocols in protocols.io to enhance the reproducibility of your results. Protocols.io assigns your protocol its own identifier (DOI) so that it can be cited independently in the future. For instructions see: https://journals.plos.org/plosone/s/submission-guidelines#loc-laboratory-protocols. Additionally, PLOS ONE offers an option for publishing peer-reviewed Lab Protocol articles, which describe protocols hosted on protocols.io. Read more information on sharing protocols at https://plos.org/protocols?utm_medium=editorial-email&utm_source=authorletters&utm_campaign=protocols.

We look forward to receiving your revised manuscript.

Kind regards,

Rosemary Bassey, Ph.D.

Academic Editor

PLOS ONE

Journal Requirements:

When submitting your revision, we need you to address these additional requirements.

1. Please ensure that your manuscript meets PLOS ONE's style requirements, including those for file naming. The PLOS ONE style templates can be found at

https://journals.plos.org/plosone/s/file?id=wjVg/PLOSOne_formatting_sample_main_body.pdf and

https://journals.plos.org/plosone/s/file?id=ba62/PLOSOne_formatting_sample_title_authors_affiliations.pdf

2. Please describe in your methods section how capacity to provide consent was determined for the participants in this study. Please also state whether your ethics committee or IRB approved this consent procedure. If you did not assess capacity to consent please briefly outline why this was not necessary in this case.

3. In the online submission form, you indicated that The data that support the findings of this study are available from the corresponding author upon reasonable request.].

All PLOS journals now require all data underlying the findings described in their manuscript to be freely available to other researchers, either 1. In a public repository, 2. Within the manuscript itself, or 3. Uploaded as supplementary information.

This policy applies to all data except where public deposition would breach compliance with the protocol approved by your research ethics board. If your data cannot be made publicly available for ethical or legal reasons (e.g., public availability would compromise patient privacy), please explain your reasons on resubmission and your exemption request will be escalated for approval.

4. Thank you for stating the following financial disclosure: [Doctor Dai claimed that this work was supported by the key project of natural science foundation of Chongqing (cstc2020jcyj-zdxmX0009), the Key project and innovation project of People's Liberation Army of China (2021HL003).]. 

Please state what role the funders took in the study.  If the funders had no role, please state: ""The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.""

If this statement is not correct you must amend it as needed.

Please include this amended Role of Funder statement in your cover letter; we will change the online submission form on your behalf.

5. Thank you for stating the following in the Competing Interests section: [Authors claimed receiving research funding from key project of nature science foundation of Chongqing (cstc2020jcyj-zdxmX0009), the Key project and innovation project of People's Liberation Army of China (2021HL003).Other authors report no biomedical financial interests or potential conflicts of interest.

All authors state that the content has not been published or submitted for publication elsewhere.].

Please confirm that this does not alter your adherence to all PLOS ONE policies on sharing data and materials, by including the following statement: ""This does not alter our adherence to  PLOS ONE policies on sharing data and materials.” (as detailed online in our guide for authors http://journals.plos.org/plosone/s/competing-interests).  If there are restrictions on sharing of data and/or materials, please state these. Please note that we cannot proceed with consideration of your article until this information has been declared.

Please include your updated Competing Interests statement in your cover letter; we will change the online submission form on your behalf.

6. Thank you for stating the following in the Acknowledgments Section of your manuscript: [Authorsclaimed that this study was supported by key project of nature science foundation of Chongqing (cstc2020jcyj-zdxmX0009), the Key project and innovation project of People's Liberation Army of China (2021HL003). The authors thank clinical doctors who devote to patients recruitment, including Dr. Dr. L. D. Hu from Geleshan Psychiatry Hospital, Dr. X. Y. Zhou from Psychiatry center of Chongqing, Dr.Y.He from 324 Hospital of Chong Qing. We appreciate the endeavor of all graduate students who participated this study as research assistants. We also thank all subjects who took part in this study, especially the clinical patients.]

We note that you have provided funding information that is not currently declared in your Funding Statement. However, funding information should not appear in the Acknowledgments section or other areas of your manuscript. We will only publish funding information present in the Funding Statement section of the online submission form.

Please remove any funding-related text from the manuscript and let us know how you would like to update your Funding Statement. Currently, your Funding Statement reads as follows: [Doctor Dai claimed that this work was supported by the key project of natural science foundation of Chongqing (cstc2020jcyj-zdxmX0009), the Key project and innovation project of People's Liberation Army of China (2021HL003).]. 

Please include your amended statements within your cover letter; we will change the online submission form on your behalf.

7. Your ethics statement should only appear in the Methods section of your manuscript. If your ethics statement is written in any section besides the Methods, please move it to the Methods section and delete it from any other section. Please ensure that your ethics statement is included in your manuscript, as the ethics statement entered into the online submission form will not be published alongside your manuscript.

8. We notice that your supplementary figures are uploaded with the file type 'Figure'. Please amend the file type to 'Supporting Information'. Please ensure that each Supporting Information file has a legend listed in the manuscript after the references list.

9. We notice that your supplementary figures are included in the manuscript file. Please remove them and upload them with the file type 'Supporting Information'. Please ensure that each Supporting Information file has a legend listed in the manuscript after the references list.

10. Please review your reference list to ensure that it is complete and correct. If you have cited papers that have been retracted, please include the rationale for doing so in the manuscript text, or remove these references and replace them with relevant current references. Any changes to the reference list should be mentioned in the rebuttal letter that accompanies your revised manuscript. If you need to cite a retracted article, indicate the article’s retracted status in the References list and also include a citation and full reference for the retraction notice.

[Note: HTML markup is below. Please do not edit.]

Reviewers' comments:

Reviewer's Responses to Questions

Comments to the Author

1. Is the manuscript technically sound, and do the data support the conclusions?

The manuscript must describe a technically sound piece of scientific research with data that supports the conclusions. Experiments must have been conducted rigorously, with appropriate controls, replication, and sample sizes. The conclusions must be drawn appropriately based on the data presented.

Reviewer #1: Yes

Reviewer #2: Yes

Reviewer #3: Yes

**********

2. Has the statistical analysis been performed appropriately and rigorously?

Reviewer #1: Yes

Reviewer #2: Yes

Reviewer #3: Yes

**********

3. Have the authors made all data underlying the findings in their manuscript fully available?

The PLOS Data policy requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data—e.g. participant privacy or use of data from a third party—those must be specified.

Reviewer #1: Yes

Reviewer #2: Yes

Reviewer #3: Yes

**********

4. Is the manuscript presented in an intelligible fashion and written in standard English?

PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here.

Reviewer #1: Yes

Reviewer #2: Yes

Reviewer #3: Yes

**********

5. Review Comments to the Author

Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters)

Reviewer #1: The manuscript by Sun D.X. and co-authors analyses the clinical data on anhedonia and depression from the side of reward network mechanism.

The manuscript is well-prepared, gives enough data to confirm the author's statements and claims.

With this in mind, presented manuscript is a good work that may be published in PLOS One journal.

Per contrary, it has several important points I would like to address to the authors and I expect they will correct them:

1. Please discuss the recent data on brain structures (that you study in your work) interactions in regulation of anhedonia and depression. I suppose there are a lot of new experimental articles that show how these brain regions interact with each other in controlling behavior employing cell and tissue histology and physiology methods.

2. The references list is very old. Two articles published on 2020 and 2021 are the newest ones in this manuscript. The authors should update the references list by adding the newer publications.

3. In addition to the study limitations, the authors should also include the perspectives subsection, where they should write in details on how potentially this work and the data may be used in further research.

4. Sometimes the English usage appears strange, please check the spelling.

Reviewer #2: This study is an interesting research topic that has demonstrated the different reward network involvement of anhedonia and depression. However, in order to increase readers' understanding, it seems necessary to revise the following parts.

1. Throughout the manuscript, certain words (aka. correlate) are repeated too much, and the fact that it is unnecessarily the first study is used repeatedly for discussion. English correction is needed throughout the paper.

2. With this study alone, it seems unreasonable for the reward network to evaluate which of the state or trace markers will be suitable. Nevertheless, if the authors describe it as suitable as a trace marker, the evidence for this should be described.

3. In the introduction, authors argued that anhedonia is a core symptom of depression, and MDD and anhedonia may have different natural mechanisms. Could you explain this issue more detail in evidence?

4. pp. 42-44. When describing the conflicting results of previous studies on decreased depression, hyperactivation was described before without mentioning a specific brain region, and hypoactivation was described later in putamen and caudate. The authors should specify the specific brain region that is hyperactivated.

5. In the last part of the introduction, the authors established two hypotheses, talking about the purpose of the study. The authors should further describe the scientific basis for this hypothesis.

6. In Figures 1-5, specific positions with the annotation (A,B,C) should be established and specify each figure location in the manuscript.

Reviewer #3: This is an observational study with a cross-sectional design that employed resting-state functional magnetic resonance imaging (rs-fMRI) to investigate patterns of functional brain connectivity. The primary objective was to compare connectivity differences across three groups: individuals with remitted depression, individuals currently experiencing a depressive episode, and individuals with no history of psychiatric disorders. The methodology was clearly described, utilizing standardized and validated instruments appropriate for the target population and suitable for the collection and analysis of neurofunctional data.

1. Is the manuscript technically sound, and do the data support the conclusions?

Although the sample size is relatively small, the study presents valuable contributions to the theoretical understanding of depression, as well as to the development of clinical management strategies. It highlights promising directions for relapse prevention and the personalization of treatment approaches.

2. Has the statistical analysis been performed appropriately and rigorously?

Yes. The statistical analysis was appropriately conducted and allowed for the exploration of the data in line with the study’s objectives.

3. Have the authors made all data underlying the findings in their manuscript fully available?

Yes, the authors have made all relevant data available.

4. Is the manuscript presented in an intelligible fashion and written in standard English?

Yes, the manuscript is clearly written and presented in standard academic English.

5. Additional Comments to the Author

The topic addressed in this manuscript is highly relevant in the fields of neuroscience and psychiatry, offering important insights into the neurobiological mechanisms underlying depression. Notably, the identification of alterations in functional brain connectivity across different phases of the disorder contributes to the growing understanding of its pathophysiology.

A key strength of the study lies in its potential to identify neural biomarkers of depression. The detection of distinct connectivity patterns among the groups studied may support the development of diagnostic and prognostic markers related to the presence, absence, or remission of the disorder. Furthermore, these findings provide a foundation for more individualized therapeutic interventions, such as neuromodulation techniques or psychotherapeutic approaches targeting specific neural circuits.

Recommendation: The manuscript is of scientific merit and relevance. It is therefore recommended for publication.

**********

6. PLOS authors have the option to publish the peer review history of their article (what does this mean?). If published, this will include your full peer review and any attached files.

If you choose “no”, your identity will remain anonymous but your review may still be made public.

Do you want your identity to be public for this peer review? For information about this choice, including consent withdrawal, please see our Privacy Policy.

Reviewer #1: No

Reviewer #2: Yes: Jae Yong Choi

Reviewer #3: No

**********

[NOTE: If reviewer comments were submitted as an attachment file, they will be attached to this email and accessible via the submission site. Please log into your account, locate the manuscript record, and check for the action link "View Attachments". If this link does not appear, there are no attachment files.]

While revising your submission, please upload your figure files to the Preflight Analysis and Conversion Engine (PACE) digital diagnostic tool, https://pacev2.apexcovantage.com/. PACE helps ensure that figures meet PLOS requirements. To use PACE, you must first register as a user. Registration is free. Then, login and navigate to the UPLOAD tab, where you will find detailed instructions on how to use the tool. If you encounter any issues or have any questions when using PACE, please email PLOS at figures@plos.org. Please note that Supporting Information files do not need this step.

PLoS One. 2025 Sep 18;20(9):e0332816. doi: 10.1371/journal.pone.0332816.r002

Author response to Decision Letter 1


25 Aug 2025

Dear Ph.D. Rosemary Bassey,

Thank you for giving us an opportunity to revise the manuscript. Please find enclosed revised version of our manuscript entitled “Reward network mechanism in anhedonia and depression” for your consideration.

Many thanks for your constructive and detailed comments on the manuscript, which substantially improves the paper. In this revision version, we have addressed all of comments made by the reviewers (see below). With these changes, we hope that the manuscript will be of more relevant to the readership of your journal.

This manuscript is not in consideration elsewhere and the author reports no conflicts of interest. Moreover, the co-author has approved the revised version making significant contributions to the writing and conceptualization of the manuscript.

If I can be of any further assistance, please do not hesitate to contact me at my email address (daiqin101@hotmail.com). Thank you for your consideration.

Yours sincerely,

Dai Qin

COMMENTS FOR THE AUTHOR:

Journal Requirements:

When submitting your revision, we need you to address these additional requirements.

1. Please ensure that your manuscript meets PLOS ONE's style requirements, including those for file naming. The PLOS ONE style templates can be found at

https://journals.plos.org/plosone/s/file?id=wjVg/PLOSOne_formatting_sample_main_body.pdf and

https://journals.plos.org/plosone/s/file?id=ba62/PLOSOne_formatting_sample_title_authors_affiliations.pdf

Author’s responding: Thank you for the detailed suggestion and revised accordingly.

2. Please describe in your methods section how capacity to provide consent was determined for the participants in this study. Please also state whether your ethics committee or IRB approved this consent procedure. If you did not assess capacity to consent please briefly outline why this was not necessary in this case.

Author’s responding: Thank you for the important suggestion and revised accordingly. The details about how capacity to provide consent in participants were added in Participants (Line 80-82) “…The exclusion criteria were as follows: current or history of any psychopathology and/or drug and alcohol abuse infection, drug dependence, allergies within the last half month, physical trauma, severe physical disease, learning or cognitive disability…” and Procedure (Line 98-101,102-103) “…The study protocol including participants’ capacity to provide consent in accordance with the Declaration of Helsinki was approved by the Ethics Committee of Human Research of the Army Medical University (2020-036-02) and Chinese Clinical Trial registry center (ChiCTR2100044258)…The potential subjects (patients and normal controls) were screened for recruitment and their capacity to provide consent by trained personnel…”

3. In the online submission form, you indicated that The data that support the findings of this study are available from the corresponding author upon reasonable request.].

All PLOS journals now require all data underlying the findings described in their manuscript to be freely available to other researchers, either 1. In a public repository, 2. Within the manuscript itself, or 3. Uploaded as supplementary information.

This policy applies to all data except where public deposition would breach compliance with the protocol approved by your research ethics board. If your data cannot be made publicly available for ethical or legal reasons (e.g., public availability would compromise patient privacy), please explain your reasons on resubmission and your exemption request will be escalated for approval.

Author’s responding: Thank you for the important suggestion and revised accordingly. We added the information in Data Availability Statement “Data Availability Statement

The behavioral data that support the findings of this study were included in Supplementary materials. Due to reframing from military funding (2021HL003 and 2023yjsB02), the neural data could not be placed publicly and was available from the corresponding author upon reasonable request. To ensure the long term stability and availability of data, the neural data was packed and stored in three copies by a non-author institution (Military Psychology Committee institute, Chinese Society of Social Psychology) to ensure persistent or long-term data storage and availability, which was available from the official email address of this committee (jsxlxzwh@163.com)” and Cover letter.

4. Thank you for stating the following financial disclosure: [Doctor Dai claimed that this work was supported by the key project of natural science foundation of Chongqing (cstc2020jcyj-zdxmX0009), the Key project and innovation project of People's Liberation Army of China (2021HL003).].

Please state what role the funders took in the study. If the funders had no role, please state: ""The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.""

If this statement is not correct you must amend it as needed.

Please include this amended Role of Funder statement in your cover letter; we will change the online submission form on your behalf.

Author’s responding: Thank you for the important suggestion and revised accordingly. See details in Funding Declaration “Doctor Dai claimed that this work was supported by Social Science Foundation of Chongqing (2023NDYB94), the Key project and innovation project of People's Liberation Army of China (2021HL003), and the education project of Army medical university (2023yjsB02). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript, only reframed the sharing of original neural data.” and Cover letter.

5. Thank you for stating the following in the Competing Interests section: [Authors claimed receiving research funding from key project of nature science foundation of Chongqing (cstc2020jcyj-zdxmX0009), the Key project and innovation project of People's Liberation Army of China (2021HL003).Other authors report no biomedical financial interests or potential conflicts of interest.

All authors state that the content has not been published or submitted for publication elsewhere.].

Please confirm that this does not alter your adherence to all PLOS ONE policies on sharing data and materials, by including the following statement: ""This does not alter our adherence to PLOS ONE policies on sharing data and materials.” (as detailed online in our guide for authors http://journals.plos.org/plosone/s/competing-interests). If there are restrictions on sharing of data and/or materials, please state these. Please note that we cannot proceed with consideration of your article until this information has been declared.

Please include your updated Competing Interests statement in your cover letter; we will change the online submission form on your behalf.

Author’s responding: Thank you for the important suggestion and revised accordingly. See details in Declaration of interest statement “Authors claimed receiving research funding from Social Science Foundation of Chongqing (2023NDYB94), the Key project and innovation project of People's Liberation Army of China (2021HL003), and the education project of Army medical university (2023yjsB02). Other authors report no biomedical financial interests or potential conflicts of interest. This does not alter our adherence to PLOS ONE policies on sharing behavioral data, only limits on original neural data sharing from military funding (2021HL003 and 2023yjsB02). All authors state that the content has not been published or submitted for publication elsewhere.” and Cover letter.

6. Thank you for stating the following in the Acknowledgments Section of your manuscript: [Authorsclaimed that this study was supported by key project of nature science foundation of Chongqing (cstc2020jcyj-zdxmX0009), the Key project and innovation project of People's Liberation Army of China (2021HL003). The authors thank clinical doctors who devote to patients recruitment, including Dr. Dr. L. D. Hu from Geleshan Psychiatry Hospital, Dr. X. Y. Zhou from Psychiatry center of Chongqing, Dr.Y.He from 324 Hospital of Chong Qing. We appreciate the endeavor of all graduate students who participated this study as research assistants. We also thank all subjects who took part in this study, especially the clinical patients.]

We note that you have provided funding information that is not currently declared in your Funding Statement. However, funding information should not appear in the Acknowledgments section or other areas of your manuscript. We will only publish funding information present in the Funding Statement section of the online submission form.

Please remove any funding-related text from the manuscript and let us know how you would like to update your Funding Statement. Currently, your Funding Statement reads as follows: [Doctor Dai claimed that this work was supported by the key project of natural science foundation of Chongqing (cstc2020jcyj-zdxmX0009), the Key project and innovation project of People's Liberation Army of China (2021HL003).].

Please include your amended statements within your cover letter; we will change the online submission form on your behalf.

Author’s responding: Thank you for the important suggestion and revised accordingly. See details in Acknowledgement “The authors thank clinical doctors who devote to patients recruitment, including Dr. Dr. L. D. Hu from Geleshan Psychiatry Hospital, Dr. X. Y. Zhou from Psychiatry center of Chongqing, Dr.Y.He from 324 Hospital of Chong Qing. We appreciate the endeavor of all graduate students who participated this study as research assistants. We also thank all subjects who took part in this study, especially the clinical patients.” and Cover letter.

7. Your ethics statement should only appear in the Methods section of your manuscript. If your ethics statement is written in any section besides the Methods, please move it to the Methods section and delete it from any other section. Please ensure that your ethics statement is included in your manuscript, as the ethics statement entered into the online submission form will not be published alongside your manuscript.

Author’s responding: Thank you for the valuable suggestion and revised accordingly. Ethic statement were moved to Procedures (Line 96-101): “All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki Declaration and its later amendments or comparable ethical standards. The study protocol including participants’ capacity to provide consent in accordance with the Declaration of Helsinki was approved by the Ethics Committee of Human Research of the Army Medical University (2020-036-02) and Chinese Clinical Trial registry center (ChiCTR2100044258)…”

8. We notice that your supplementary figures are uploaded with the file type 'Figure'. Please amend the file type to 'Supporting Information'. Please ensure that each Supporting Information file has a legend listed in the manuscript after the references list.

Author’s responding: Thank you for the important suggestion and revised accordingly. All supplementary Figures were uploaded as 'Supporting Information'.

9. We notice that your supplementary figures are included in the manuscript file. Please remove them and upload them with the file type 'Supporting Information'. Please ensure that each Supporting Information file has a legend listed in the manuscript after the references list.

Author’s responding: Thank you for the important suggestion and revised accordingly. All supplementary Figures had a legend listed in the manuscript after the references list and were uploaded as 'Supporting Information'.

10. Please review your reference list to ensure that it is complete and correct. If you have cited papers that have been retracted, please include the rationale for doing so in the manuscript text, or remove these references and replace them with relevant current references. Any changes to the reference list should be mentioned in the rebuttal letter that accompanies your revised manuscript. If you need to cite a retracted article, indicate the article’s retracted status in the References list and also include a citation and full reference for the retraction notice.

Author’s responding: Thank you for the important suggestion and revised accordingly. We checked all references and made minor revisions in volume and pages in some of references (11, 12, 45), and confirmed that the references were complete and correct in the current version.

Reviewer #1:

The manuscript by Sun D.X. and co-authors analyses the clinical data on anhedonia and depression from the side of reward network mechanism.

The manuscript is well-prepared, gives enough data to confirm the author's statements and claims.

With this in mind, presented manuscript is a good work that may be published in PLOS One journal.

Author’s responding: Many thanks for your constructive and detailed comments on the manuscript, which substantially improves the paper.

Per contrary, it has several important points I would like to address to the authors and I expect they will correct them:

1. Please discuss the recent data on brain structures (that you study in your work) interactions in regulation of anhedonia and depression. I suppose there are a lot of new experimental articles that show how these brain regions interact with each other in controlling behavior employing cell and tissue histology and physiology methods.

Author’s responding: Thank you for the valuable suggestion and revised accordingly. We described latest reporting about neural mechanism in regulation of anhedonia and depression in 1st and 2nd paragraph of Introduction (Line 12-14, 29-32): “…Blunted left ventral striatum response to reward was associated with a lifetime depression diagnosis [8]. Recent review indicated that compared with healthy controls, patients with MDD exhibited common activity decreases in the right striatum (putamen, caudate) and subgenual ACC [9]…. Change in anhedonia scores negatively correlated with rsFC after antidepressant treatment [17]. A previous study further reported that anhedonia symptom and depressive mood were associated with similar striatal circuits in MDD patients with money-reward task [16]. Indeed, RN was indicated associated with both anhedonia and depression [18]…”

2. The references list is very old. Two articles published on 2020 and 2021 are the newest ones in this manuscript. The authors should update the references list by adding the newer publications.

Author’s responding: Thank you for the important suggestion and revised accordingly. We added 14 recent literatures in this version (literature 6, 8, 9, 17, 18, 19, 21-22, 24-26, 35, 46, 47). See references for details.

3. In addition to the study limitations, the authors should also include the perspectives subsection, where they should write in details on how potentially this work and the data may be used in further research.

Author’s responding: Thank you for the inspiring suggestion and revised accordingly. A separate paragraph about the perspective of current findings were added after Limitation and before Conclusion (Line 293-302): “Notably, this study included patients with current and remitted depression and confirmed that MDD and RMD patients possess different RN pattern, as well as depressive episode and anhedonia. The findings help to suggest candidate cortex in the treatment of depression. Specifically, caudate involves more in remitted depression, which might be an indicator of remitted stage, and be a potential target in future antidepressant treatment such as deep brain stimulation or medication. Putamen indicates only anhedonia but not depressive episode, which might be used to discriminate anhedonia and depressive episode. Insula and inferior frontal involve in both depressive episode and anhedonia, which might be cortex markers of both situations. Notably, AC and thalamus are trait-like markers of both current and remitted depression, which might involve in different stages of depressive progress, and reflected trait-like neura

Attachment

Submitted filename: Revision interpretation for RN R1.docx

pone.0332816.s008.docx (57.5KB, docx)

Decision Letter 1

Rosemary Bassey

4 Sep 2025

Reward network mechanism in anhedonia and depression

PONE-D-25-24743R1

Dear Dr. Qin Dai,

We’re pleased to inform you that your manuscript has been judged scientifically suitable for publication and will be formally accepted for publication once it meets all outstanding technical requirements.

Within one week, you’ll receive an e-mail detailing the required amendments. When these have been addressed, you’ll receive a formal acceptance letter and your manuscript will be scheduled for publication.

An invoice will be generated when your article is formally accepted. Please note, if your institution has a publishing partnership with PLOS and your article meets the relevant criteria, all or part of your publication costs will be covered. Please make sure your user information is up-to-date by logging into Editorial Manager at Editorial Manager® and clicking the ‘Update My Information' link at the top of the page. For questions related to billing, please contact billing support.

If your institution or institutions have a press office, please notify them about your upcoming paper to help maximize its impact. If they’ll be preparing press materials, please inform our press team as soon as possible -- no later than 48 hours after receiving the formal acceptance. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information, please contact onepress@plos.org.

Kind regards,

Rosemary Bassey, Ph.D.

Academic Editor

PLOS ONE

Additional Editor Comments (optional):

Reviewer #1:

Reviewer #2:

Reviewers' comments:

Reviewer's Responses to Questions

Comments to the Author

1. If the authors have adequately addressed your comments raised in a previous round of review and you feel that this manuscript is now acceptable for publication, you may indicate that here to bypass the “Comments to the Author” section, enter your conflict of interest statement in the “Confidential to Editor” section, and submit your "Accept" recommendation.

Reviewer #1: All comments have been addressed

Reviewer #2: All comments have been addressed

**********

2. Is the manuscript technically sound, and do the data support the conclusions?

The manuscript must describe a technically sound piece of scientific research with data that supports the conclusions. Experiments must have been conducted rigorously, with appropriate controls, replication, and sample sizes. The conclusions must be drawn appropriately based on the data presented.

Reviewer #1: Yes

Reviewer #2: Yes

**********

3. Has the statistical analysis been performed appropriately and rigorously?

Reviewer #1: Yes

Reviewer #2: Yes

**********

4. Have the authors made all data underlying the findings in their manuscript fully available?

The PLOS Data policy requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data—e.g. participant privacy or use of data from a third party—those must be specified.

Reviewer #1: Yes

Reviewer #2: No

**********

5. Is the manuscript presented in an intelligible fashion and written in standard English?

PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here.

Reviewer #1: Yes

Reviewer #2: Yes

**********

6. Review Comments to the Author

Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters)

Reviewer #1: The authors have cleared all the points and answered all my questions. The manuscript may now be accepted for publication.

Reviewer #2: Thank you very much. All comments made by reviewers were properly reflected in the revised manuscript.

**********

7. PLOS authors have the option to publish the peer review history of their article (what does this mean?). If published, this will include your full peer review and any attached files.

If you choose “no”, your identity will remain anonymous but your review may still be made public.

Do you want your identity to be public for this peer review? For information about this choice, including consent withdrawal, please see our Privacy Policy.

Reviewer #1: No

Reviewer #2: Yes: Jae Yong Choi

**********

Acceptance letter

Rosemary Bassey

PONE-D-25-24743R1

PLOS ONE

Dear Dr. Dai,

I'm pleased to inform you that your manuscript has been deemed suitable for publication in PLOS ONE. Congratulations! Your manuscript is now being handed over to our production team.

At this stage, our production department will prepare your paper for publication. This includes ensuring the following:

* All references, tables, and figures are properly cited

* All relevant supporting information is included in the manuscript submission,

* There are no issues that prevent the paper from being properly typeset

You will receive further instructions from the production team, including instructions on how to review your proof when it is ready. Please keep in mind that we are working through a large volume of accepted articles, so please give us a few days to review your paper and let you know the next and final steps.

Lastly, if your institution or institutions have a press office, please let them know about your upcoming paper now to help maximize its impact. If they'll be preparing press materials, please inform our press team within the next 48 hours. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information, please contact onepress@plos.org.

You will receive an invoice from PLOS for your publication fee after your manuscript has reached the completed accept phase. If you receive an email requesting payment before acceptance or for any other service, this may be a phishing scheme. Learn how to identify phishing emails and protect your accounts at https://explore.plos.org/phishing.

If we can help with anything else, please email us at customercare@plos.org.

Thank you for submitting your work to PLOS ONE and supporting open access.

Kind regards,

PLOS ONE Editorial Office Staff

on behalf of

Dr. Rosemary Bassey

Academic Editor

PLOS ONE

Associated Data

    This section collects any data citations, data availability statements, or supplementary materials included in this article.

    Supplementary Materials

    S1 Fig. Flow chart of participant recruitment.

    (TIF)

    pone.0332816.s001.tif (189.4KB, tif)
    S2 Fig. The reward network (RN, ventral striatum seed, 21, 9, 0).

    (TIF)

    pone.0332816.s002.tif (1.2MB, tif)
    S3 Fig. Scatterplots of correlation between functional connectivity and depressive anhedonia.

    (TIF)

    pone.0332816.s003.tif (290.6KB, tif)
    S4 Fig. Group difference on function connectivity with the whole brain (striatum seed).

    (TIF)

    pone.0332816.s004.tif (1.8MB, tif)
    S5 Fig. Bigger thalamus volume in MDD compared with the RMD group.

    (TIFF)

    S1 Data. RN group data.

    (XLSX)

    pone.0332816.s006.xlsx (13.8KB, xlsx)
    Attachment

    Submitted filename: Revision interpretation for RN R1.docx

    pone.0332816.s008.docx (57.5KB, docx)

    Data Availability Statement

    The behavioral data that support the findings of this study were included in Supplementary materials. Due to reframing from military funding (2021HL003 and 2023yjsB02), the neural data could not be placed publicly and was available from the corresponding author upon reasonable request. To ensure the long term stability and availability of data, the neural data was packed and stored in three copies by a non-author institution (Military Psychology Committee institute, Chinese Society of Social Psychology) to ensure persistent or long-term data storage and availability, which was available from the official email address of this committee (jsxlxzwh@163.com).


    Articles from PLOS One are provided here courtesy of PLOS

    RESOURCES